I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation

The article argues for leaning into dividend defensives amid a market trading sideways, highlighting AbbVie’s immunology-driven rebound with 2026 forecasts of ~10% revenue and ~40% earnings growth and a ~2.75% forward dividend yield (avg ~6% annual dividend growth). Chevron is positioned for ~10% annualized earnings growth to 2030 if Brent stays above $70/bbl, with a ~3.75% forward yield and ~6% dividend growth, while PepsiCo is framed as a contrarian opportunity at a ~4.4% forward yield despite weaker U.S. share and an 18x vs. Coca-Cola’s 25x forward earnings multiple. Overall, the pieces imply steady cash returns with modest upside if sentiment improves.

Analysis

This is less a stock-picker's note than a factor call: in a sideways tape, the market tends to pay for visible cash return and penalize anything that looks cyclically fragile. That creates a relative bid for names that can compound dividends without needing heroic revenue acceleration, but the spread only holds if earnings revisions stay intact and rates do not reprice sharply higher.

ABBV is the cleanest quality-growth expression because the market will tolerate a premium as long as immunology remains the engine and the pipeline fill-in story does not dilute capital allocation. The key second-order risk is M&A execution: once a large tuck-in becomes part of the story, investors will focus on leverage and integration rather than the dividend streak.

CVX is a different animal: the investment case is not spot oil, it is the credibility of capital discipline. If crude remains above the threshold where buybacks and dividend growth are self-funding, the multiple can grind higher; if crude slips, the market will quickly strip out the "quality energy" premium and treat it like beta.

PEP is the most interesting contrarian because the issue is not balance-sheet stress, it is sentiment around U.S. share loss. If that stabilizes, the valuation gap to KO can narrow; if it doesn't, the yield alone will not prevent further multiple compression. In the near term, this is an earnings-guidance trade; over 6-18 months, it is about whether dividend growth can outrun inflation and preserve real total return.

Key Decisions for Investors

• Long ABBV on pullbacks over the next 1-3 months; favor a buy-the-dip entry ahead of the next guidance cycle. Falsifier: any slowdown in immunology growth or a balance-sheet reset tied to APGE integration.
• Long CVX vs short XLE for 3-6 months to isolate capital-discipline outperformance versus generic energy beta. Falsifier: Brent below the discipline threshold or renewed capex creep.
• Pair long PEP / short KO on a 6-12 month mean-reversion view if the market keeps paying up for KO's quality premium. Better entry is after the next quarter confirms U.S. volume stabilization; downside is continued share erosion and no margin offset.
• If rates back up materially, reduce all three names and rotate toward the highest free-cash-flow yield rather than the highest dividend yield; these are defensives, not immune assets.